Related Experiment Videos
Gonadal function following ABVD therapy for Hodgkin's disease
S S Kulkarni1, P S Sastry, T K Saikia
1Department of Medical Oncology, Tata Memorial Hospital, Parel, Bombay, India.
American Journal of Clinical Oncology
|August 1, 1997
Summary
The ABVD chemotherapy regimen shows better preservation of gonadal function in male Hodgkin
Area of Science:
- Oncology
- Reproductive Endocrinology
- Clinical Research
Background:
- Hodgkin's disease treatment can impact male fertility.
- Assessing gonadal function post-chemotherapy is crucial for long-term patient well-being.
Purpose of the Study:
- To evaluate the effects of ABVD chemotherapy on male gonadal function.
- To compare gonadal function between ABVD and ABVD with COPP/MOPP regimens.
Main Methods:
- Assessed 38 male patients with Hodgkin's disease in remission.
- Evaluated secondary sexual characteristics, sexual habits, and fatherhood.
- Performed semen analysis and measured serum hormone levels (FSH, LH, testosterone).
Main Results:
- ABVD therapy resulted in significantly lower rates of azoospermia (infertility) compared to ABVD with COPP/MOPP.
- Patients receiving ABVD had higher normal follicle-stimulating hormone (FSH) levels.
- Three patients fathered children after ABVD treatment.
Conclusions:
- ABVD chemotherapy is associated with better preservation of male gonadal function.
- Combination chemotherapy including COPP/MOPP significantly impairs gonadal function.
- ABVD offers a more favorable option for maintaining fertility in Hodgkin's disease survivors.